Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model

BACKGROUND: The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is known about the role of the human CD141(+) DC cDC1 equivalent in patients with melanoma. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yoke Seng, O'Brien, Liam J, Walpole, Carina M, Pearson, Frances E, Leal-Rojas, Ingrid M, Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew, Radford, Kristen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978242/
https://www.ncbi.nlm.nih.gov/pubmed/33737342
http://dx.doi.org/10.1136/jitc-2020-001963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978242/
https://www.ncbi.nlm.nih.gov/pubmed/33737342
http://dx.doi.org/10.1136/jitc-2020-001963

Ejemplares similares